A. Introduction
Lymphokine-activated killer (LAK) cells are known to lyse fresh solid tumor cells in vitro [1] , and clinical studies suggest that adoptive immunotherapy with LAK cells and interleukin-2 (IL-2) may be a promising approach in the treatment of solid tumors [2, 3] . As only few data are available on the LAK cell system in connection with human leukemia [4, 5] , we investigated the induction of LAK cells against human leukemia cells in vitro and studied the augmentation of cytotoxic mechanisms which may be achieved by the combined application of different lymphokines or the coculturing of effector cells with tumor cells.
B. Materials and Methods

I. Lymphokines
Recombinant IL-2 and rIFN-1' were generous gifts from the Glaxo Institute of Molecular Biology, Geneva, and the Ernst-Boehringer Institute, VieI?-na.
II. Induction of LAK Cells
Allogeneic human LAK cells were generated from peripheral blood mononuclear cells obtained from healthy volunteers and cultured (1 x 10 6 jml) for 6 days with rIL-2 (1000 Djml). In some experiments, we induced LAK activity from bone mar- 
IV. Cytotoxicity Assay
Lymphokine-activated killer cell activity was determined in a standard 4-h SlCr release assay using 5 x 10 3 target cells and various effector-to-target (E: T) ratios.
c. Results and Discussion
Leukemic cells from 62 patients were evaluated for their susceptibility to the lytic effect of allogeneic LAK cells. A significant lysis (defined as over 20% specific lysis at an E: T ratio of 100: 1) was found in about two-thirds of the leukemias examined (Table 1) . No substantial differences could be detected between myeloid and lymphoid leukemias or with regard to the immunological phenotype.
Target cells n
Cytotoxicity (% specific lysis) E:T 100:1 There is growing evidence that leukemia patients have impaired natural killer (NK) cell functions, and this may contribute to leukemogenesis [5, 7] . We therefore studied the possibility of using IL-2 to activate NK cells ofleukemic patients. In the presence of IL-2, long-term culturing of mononuclear cells from 70 AMl All 60 (Fig. 1) . These cultures of leukemic cells and residual normal mononuclear cells resemble tumor-infiltrating lymphocytes (TILs), which are known to be more active than LAK cells generated from peripheral blood [8] . As demonstrated, the application of IL-2 in vitro can result in an activation and expansion of LGL even in highly leukemic patients, suggesting that the generation of LAK cells by IL-2 in vivo, e.g., after chemotherapy, may be therapeutically useful in preventing the relapse or spread of leukemia.
Reports that endogenous IFN-y is required for IL-2 induction of LAK cells [9] led us to conjecture that it might be possible to augment LAK activity by addition of rIFN-y during the activation process. The results of our studies show that the combined application of rIFN-y and rIL-2 can improve the effectivity of cytotoxic mechanisms even at a low E: T ratio of2.5: 1 (Fig. 2) . The sequential ad- Induction of LAK cells Cytotoxicity (% specific lysis) PBMCs with IL-2 alone (Table 2 ). This may be due to target cell structures being present during the activation process and giving additional signals for the generation of LAK cells. The results of these studies suggest that IL-2-induced lymphokine-activated killer (LAK) cells may be of great value in the treatment of leukemia, especially when the tumor burden is low, e.g., during maintenance chemotherapy to eliminate minimal residual disease or in early relapse. The combined application of different lymphokines or the coculturing of effector cells with IL-2 and tumor cells are possible approaches for improving the effectivity of cytotoxic mechanisms.
